Tempus AI (TEM) stock saw a positive improvement to its Relative Strength (RS) Rating on Thursday, rising from 66 to 78.
When To Sell Stocks To Lock In Profits And Minimize Losses
This unique rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database.
Decades of market research shows that the best stocks typically have an RS Rating of at least 80 as they begin their biggest runs. See if Tempus AI stock can continue to rebound and hit that benchmark.
Tempus AI working stock is working on a cup without handle with a 74.83 entry. See if it can clear the breakout price in volume at least 40% above average.
The healthcare technology firm posted 0% earnings growth in its most recent report, while sales growth came in at 90%.
Tempus AI stock holds the No. 5 rank among its peers in the Medical-Research Equipment/Services industry group. Medpace Holdings (MEDP) is the top-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
YOU MAY ALSO LIKE:
Learn How To Time The Market With IBD's ETF Market Strategy
Find Today's Best Growth Stocks To Watch With IBD 50
Find The Best Long-Term Investments With IBD Long-Term Leaders
How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.